Perrigo/Padagis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Perrigo/Padagis (US): 6 reconciled FDA prescription therapies, $29.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$29.4M
2024 Medicare Part D Spend$23.7M
2024 Medicaid Spend$5.7M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Perrigo across sibling Meru public-data platforms.